Retrospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Jul 15, 2024; 15(7): 1489-1498
Published online Jul 15, 2024. doi: 10.4239/wjd.v15.i7.1489
Association between glucose-lowering drugs and circulating insulin antibodies induced by insulin therapy in patients with type 2 diabetes
Peng Zhang, Qing Jiang, Bo Ding, Reng-Na Yan, Yun Hu, Jian-Hua Ma
Peng Zhang, Bo Ding, Reng-Na Yan, Jian-Hua Ma, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, Jiangsu Province, China
Qing Jiang, Yun Hu, Department of Endocrinology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi Medical Center, Wuxi 214000, Jiangsu Province, China
Co-first authors: Peng Zhang and Qing Jiang.
Co-corresponding authors: Yun Hu and Jian-Hua Ma.
Author contributions: Zhang P and Jiang Q are co-authors and contributed equally to this article. Jiang Q and Hu Y wrote and reviewed the manuscript; Zhang P, Ding B and Yan RN contributed to the data collection; Hu Y and Ma JH are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors have read and agreed to the published version of the manuscript.
Supported by The National Key R and D Program of China, No. 2018YFC1314103; and The National Natural Science Foundation of China, No. 81870563 and No. 82270838.
Institutional review board statement: The study was approved by the institutional research committee (No: KY20190926-01).
Informed consent statement: This is a retrospective study performed by review of participants’ electronic clinical records only and therefore, patient consent was not necessary and was not obtained.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: Authors are happy to share the data on request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian-Hua Ma, MD, Chief Physician, Professor, Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, No. 32 Gongqinqtuan Road, Yuhua District, Nanjing 210000, Jiangsu Province, China. majianhua196503@126.com
Received: December 19, 2023
Revised: April 8, 2024
Accepted: May 27, 2024
Published online: July 15, 2024
Processing time: 202 Days and 2.6 Hours
Core Tip

Core Tip: In this study, we found that the proportion of positive insulin antibodies (IAs) was high in type 2 diabetes patients receiving exogenous insulin therapy. Positive IAs was correlated with high fasting blood glucose, insulin glargine was associated with the lowest IA levels among the insulin regimens, and the use of insulin secretagogues, metformin, and dipeptidyl peptidase-4 inhibitors was correlated with decreased IA levels.